Triple DAA regimen cures hepatitis C patients with rapid response in just 3 weeks

Triple DAA regimen cures hepatitis C patients with rapid response in just 3 weeks
Direct-acting antiviral agents (DAAs) used in interferon-free regimens have already brought about a revolution in treatment for chronic hepatitis C, but researchers continue to search for therapies that are more effective, easier to use and less expensive.
Read more here.

More deadly than HIV: Hepatitis C, a silent killer
Hep C is sneaky. It's not like a cold where you immediately recognize it through symptoms like a cough or soar throat. It often remains silent for decades, until it's already damaged the liver. An estimated 3 million people in the U.S. have it, and the …
Read more here.

Expensive new Hep C drugs may be cost-effective even for early disease
Treating hepatitis C with expensive new medicines at the earliest signs of liver damage improves patients' health and is also cost-effective, a new computer simulation suggests. "Going into this, I expected to find it did make sense to wait until there …
Read more here.

Clinical impact of effective HCV DAAs: referrals for liver transplant drop
Some studies have shown improvements in liver function and clinical symptoms of liver disease in people with cirrhosis after a sustained virologic response to treatment of hepatitis C with direct-acting antivirals. Whether this benefit extends to …
Read more here.

Utility of Translocator Protein (18 kDa) as a Molecular Imaging Biomarker to
In Japan, cirrhosis is mainly caused by hepatitis virus, with hepatitis C virus accounting for 70% of cases and hepatitis B virus accounting for 20% of cases, as reported by the National Center for Global Health and Medicine (Chiba, Japan). Persistent …
Read more here.

Abuse, Inflated Prices Spur MD Vote to Kill Ads
Antibiotics was one of only two classes of drugs that showed a decrease in use during 2012 along with sex hormones among women, which decreased from 19 percent to 11 percent, possibly driven by a decline in hormone treatment for menopause. … Harvoni …
Read more here.

Medicaid denies half of prescriptions for new hepatitis C drugs, Penn study finds
State Medicaid programs in the Philadelphia region denied nearly half the coverage requests for the most effective – and expensive – treatments for chronic hepatitis C, according to a University of Pennsylvania study that will be presented on Monday.
Read more here.


Leave a Reply